Option chain shows key data for Adlai Nortye's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Adlai Nortye.

Adlai Nortye (NASDAQ:ANL) Stock, Option Chain

Adlai Nortye

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

xr:d:DAFtH5xd8iU:2,j:4016486423666345323,t:23083115

News

Intraday Update

Markets

Movers

Trading Ideas

AMBC

ASNS

BGXX

BNED

CLEU

CMPS

CVAC

DLTR

DOYU

FBLG

FRES

GDHG

GWRE

HLTH

JDZG

JEWL

MITQ

MLGO

MMYT

MNMD

MPLN

MYND

NDRA

NVAX

NVVE

OLLI

SFIX

SGRP

SILO

SOBR

SYTA

THMO

UMAC

UNFI

VLCN

VRNT

VSTE

WKME

XTIA

Why Lands&#39; End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Image22

COIN

CRML

CSGP

LXEO

LXRX

MSTR

MTTR

NGVT

RIOT

Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday

Tesla - logo

Pre-Market Outlook

AILE

IAUX

INFA

MNDR

TSLA

Tesla, Li Auto And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye Ltd

Aton Resources Inc

ANFIELD ENERGY INC by Anfield Energy Inc.

Anfield Energy Inc

Press Releases

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Management

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Earnings

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Elicio Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

I-MAB

Lexeo Therapeutics

Macrogenics

MediciNova

OncoCyte

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

TScan Therapeutics

Tenaya Therapeutics

Vigil Neuroscience

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Exicure

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Comments

Adlai Nortye

Adlai Nortye (ANL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga